Ironwood Pharmaceuticals Inc【IRWD】株式ニュース | ADVFN

US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Ironwood Pharmaceuticals Inc (IRWD)
Ironwood Pharmaceuticals Inc (IRWD) ニュース

Ironwood Pharmaceuticals Inc (IRWD)

3.66

-0.12

(-3.17%)

終了 1月21日 6:00AM

3.66

0.00

(0.00%)

取引時間後: 8:55AM

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024

– Data from pivotal Phase III STARS study in short bowel syndrome with intestinal failure (SBS-IF) accepted as late-breaker oral presentation on...

Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2024 investor update conference call and webcast at...

Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)

– First prospective trial of a glucagon-like peptide (GLP-2) analog in SR GI aGVHD – – Results up to Day 91 show that apraglutide in SR GI aGVHD...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

– Apraglutide met the primary endpoint of relative change from baseline in actual weekly parenteral support (PS) volume at week 24, driven by...

Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference

– Apraglutide nutritional data from STARS Nutrition Phase 2 study in adult patients who have short bowel syndrome with intestinal failure and...

Form 8-K - Current report

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance

– LINZESS® (Iinaclotide) 2023 U.S. net sales of $1.1 billion, an increase of 7% year-over-year, driven by EUTRx prescription demand growth of 10...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

2
3
4
次へ

ProLiberty

ProLiberty 5月前

Possible buy below $5? Any chance the VectivBio acquisition ends up not being as horrible as it currently appears? When might the acquired asset begin to generate revenue?

Monksdream

Monksdream 10月前

philaya

philaya 10月前

sold...
fast trading.

philaya

philaya 10月前

Using radar...
Got this today

Dubster watching

Dubster watching 11月前

BabySealHugger

BabySealHugger 4年前

Hearing rumblings of IRWD this week. Anyone else?

whytestocks

whytestocks 4年前

Just In: $IRWD Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call Transcript

Image source: The Motley Fool. Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Q3 2020 Earnings Call Nov 6, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call Trans...

Find out more IRWD - Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call Transcript

whytestocks

whytestocks 4年前

Just In: $IRWD Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment

– Trial did not achieve statistically significant improvement in heartburn severity (primary endpoint) – – Ironwood plans to implement organizational restructuring, resulting in expected headcount reduction of approximately 100 full-time employees, or near...

In case you are interested IRWD - Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment

whytestocks

whytestocks 6年前

News: $IRWD Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

– Phase IIIb study met all primary and secondary endpoints with statistical significance and demonstrated that linaclotide improved the overall abdominal symptoms of bloating, pain and discomfort in adults with IBS-C – – Results further support the efficacy and s...

Got this from https://marketwirenews.com/news-releases/ironwood-and-allergan-report-positive-topline-data-from-phase-iiib-trial-of-linzess-xae-linaclotide-in-adults-with-irritable-bowel-syndrome-with-constipation-ibs-c--8377600.html

ClayTrader

ClayTrader 6年前

* * $IRWD Video Chart 05-17-2019 * *

Link to Video - click here to watch the technical chart video

stocktrademan

stocktrademan 6年前

IRWD buy 11.365

https://www.ironwoodpharma.com/

normal chart

log chart

chemist99

chemist99 6年前

epilogue

SGYP down to 3 pennies after hours today

the signs were all there, but you had to be willing to read them.

if there is a list somewhere, like, "always go on the opposite end of the trade for all recommendations from these institutions" - most of the SGYP institutional investors should definitely be on it IMHO.

chemist99

chemist99 6年前

How did that work out for you;)

chemist99

chemist99 7年前

knew all too well what was going on behind the Synergy scenes;

http://www.nj.com/business/index.ssf/2012/08/bristol-myers_drug_flop_erases.html

if you make a multinational company lose a couple billion $ in short order & leave them stuck with trial deaths, AND expect anyone in the pharmaceutical industry ever to trust you again, you need to have your head examined imo. he's probably looking under his car every morning...

there's a really nice package deal available for you though from the experienced crew, if you're still game for it:

Synergy, $6 in January, now on sale at $1.90, Trovagene, went public at $24, now marked down to 51 cents for quick clearance, and ContraVir, $5 as recently as 2015, but now available for just 49 cents! Yes, you get all three of these made-to-be-sold companies for just $2.90! And, if you act now, we'll throw in 10 shares of Callisto Pharmaceuticals, a company which sank beneath the waves with Cap'n Gary at the helm!

chemist99

chemist99 7年前

Enjoy the front row seat to the final act of the drama, sure was expensive enough...

chemist99

chemist99 7年前

Inoviorulez

Inoviorulez 8年前

https://seekingalpha.com/article/4089539-ironwood-will-press-good-fight-gerd

chemist99

chemist99 8年前

chemist99

chemist99 8年前

chemist99

chemist99 9年前

brownsfan407

brownsfan407 9年前

I did 10,000 shares on that one, didn't get in at the low, but out close to the top. Flipped it into sgyp in the low 3's

chemist99

chemist99 9年前

thanks for bringing it to my attention! that was nice, ~7.30s to $10.24 in less than a month, 30+% !
Hope you didn't miss it :) ?

brownsfan407

brownsfan407 9年前

you were right, we saw 7's this week. 52 week low

chemist99

chemist99 9年前

SGYP short volume 25 million plus now...looks like the hedgefunds are in the business to lose money then ?

brownsfan407

brownsfan407 9年前

under 10 coming your way soon. the trend is your friend

brownsfan407

brownsfan407 9年前

IRWD, 10.71 new 52 week low fact, not rant
8.00 in September lows

chemist99

chemist99 9年前

no pain data, skewed side effect profile = no partner IMO.

no partner = slim chance, if any, of competing in the marketplace for a primary care drug with an army of people promoting the first-to-market competitor, IMO.

simple as that.

rant all you want. doesn't change the fact that Phase III CIC data are out - and still no buyout & no partnership despite the "hey we're for sale" press article LOL.

that, and the low (~30%) institutional ownership of SGYP compared with IRWD (~100%), combined with the ~22 mill. short volume for SGYP speak volumes...

brownsfan407

brownsfan407 9年前

IRWD pennies of 51 week low, while market booms. Stock price heading in the same direction as the diarrhea it causes. despite misinformation by IRWD propagandist.. BTW, I bought a boatload of warrants at .36, now 4.00. I can be very patient for the next explosion. 2 phase 3 results and an NDA by year end

brownsfan407

brownsfan407 9年前

from an IRWD board? nice, just a little biased. Don't try to be naïve, you have no idea what is going on behind the scenes. and like I said you have lots of holders, but yahoo stats says 3 percent own over 5 percent, and that 3 percent includes insider holdings. Everyone owns a little. Cerrone TOOK 1/2 year with inhibitex, to get top buck, we have only been a month here. 4 catalysts by year end. we are up 165 percent, you? your short at 4 dollars is a FAILED trade

chemist99

chemist99 9年前

sooner or later the Wall Street hysteria, fanned by a couple of hyperbolic analyst op ed pieces, will be over; - the music will stop, people will wake up & valuations will adjust to reality. they always do.

I quote a comment of someone from "the trenches" posted on the IRWD CP board, who puts it in quite simple (& blunt) terms:

anonymous, Jul 22, 2015 at 9:37 AM
(quote) ...." Less diarrhea, yes but with that is less efficacy. You can't treat cic with no diarrhea and have the same efficacy. So you think you can hire a third of the reps ? So roughly 1 rep per state to grow the constipation market of 50 million? This is a primary care drug linzess has over 3000 people promoting it. When it is all said and done 80 percent of volume will come from pcp. You need a partner and despite your so called stellar efficacy and no side effects no one is stepping up. No pain data and skewed side effect data equals no partner. We developed plecanatide and linaclotide and kept linzess. I'm gonna go with the MIT scientists who discovered GCC on this one..."

http://www.cafepharma.com/boards/threads/we-should-buy-synergy.583049/

brownsfan407

brownsfan407 10年前

I don't know the answer, but do you think they are happy with the price DEpreciation, under 11, it has been YEARS since it has been that low

chemist99

chemist99 10年前

IRWD:
% of Shares Held by Institutional & Mutual Fund Owners: 110%
% of Float Held by Institutional & Mutual Fund Owners: 112%
Number of Institutions Holding Shares: 163

SGYP:
% of Shares Held by Institutional & Mutual Fund Owners: 29%
% of Float Held by Institutional & Mutual Fund Owners: 32%
Number of Institutions Holding Shares: 90

source: Yahoo finance 07/22/15

brownsfan407

brownsfan407 10年前

% of Shares Held by All Insider and 5% Owners: 2 percent. surprisingly low. lots with their toes in the water, but no ringing endorsements

brownsfan407

brownsfan407 10年前

I can explain the price drop in facts, but I can't help you to understand it

brownsfan407

brownsfan407 10年前

Chemist, you the only one here? Looks like it

brownsfan407

brownsfan407 10年前

but our price is going up, I am sorry, which way is this price going? It is not going to be long before our price eclipses yours

chemist99

chemist99 10年前

Sgyp new short volume ~ 22 mill; - go figure ??

brownsfan407

brownsfan407 10年前

chemist, short up to 17 mill, too bad you can't use your moniker to reformulate this drug into something better, but then again, what chemistry do you need to use a virus?

brownsfan407

brownsfan407 10年前

hot 6 page found in nature thing working for you? I am having trouble with my pixels, did wedbush lower the target to 11? that's lower than the current price

brownsfan407

brownsfan407 10年前

6/15 was days before the phase 3 results. I bet some more shorted the 9 down to 8 to cover the earlier bad trade. We hire 2 more big guns today, and the pump articles and increasing price targets are like ants around a popsicle on a picnic, they are everywhere. Synergy will do ma secondary at 13, pay back the loan, and actually lower their share count, and knock off the interest

chemist99

chemist99 10年前

yes, IRWD short interest up to ~16 million shares, but SGYP up even more to about ~21.5 million shares per 06/15 :
http://www.nasdaq.com/symbol/sgyp/short-interest

the hedge funds must be in the business to lose money, I guess...

brownsfan407

brownsfan407 10年前

Chemist, Last SI up 2 million, are there folks betting on this going down. are you hedged? Sgyp set to double

brownsfan407

brownsfan407 10年前

How about your long position here? 1/3 the diarrhea rate for plecanatide, and filing NDA in November. Has to severely stunt the growth here. What is the adage, the market is forward looking? However, maybe you can clarify. The guy who took IRWD through the NDA process, does he still work for you?

brownsfan407

brownsfan407 10年前

In a few months the ticker symbol for Synergy may not exist, in a perfect world

chemist99

chemist99 10年前

No short no loss. Let's compare notes again in a few months. Enjoy it while it lasts??

brownsfan407

brownsfan407 10年前

what did you lose on the short? 6 bucks per share? and now, your long shares here are severely compromised. I would have some compassion for you if it were not for your past smugness and haughtiness

brownsfan407

brownsfan407 10年前

Game, set, match, plecanatide is clearly better. Cannot dispute the numbers, as the 600 rode the 89 percent gain

chemist99

chemist99 10年前

oh well, it served it's purpose, I suppose :)

brownsfan407

brownsfan407 10年前

check out lpcn, oral trt, NDA BY Q3, pre-term birth PILL too. Low float monster

chemist99

chemist99 10年前

lol.

a little knowledge can be a dangerous thing.

Ironwood Pharmaceuticals

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約